Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Medpace Holdings stock

MEDP
US58506Q1094
A2APTV

Price

360.31
Today +/-
+10.06
Today %
+2.98 %

Medpace Holdings stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Medpace Holdings stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Medpace Holdings stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Medpace Holdings stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Medpace Holdings's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Medpace Holdings Stock Price History

DateMedpace Holdings Price
12/17/2024360.31 undefined
12/16/2024349.74 undefined
12/13/2024345.93 undefined
12/12/2024347.43 undefined
12/11/2024341.50 undefined
12/10/2024341.95 undefined
12/9/2024352.22 undefined
12/6/2024350.53 undefined
12/5/2024342.30 undefined
12/4/2024346.31 undefined
12/3/2024339.27 undefined
12/2/2024342.36 undefined
11/29/2024340.63 undefined
11/27/2024338.96 undefined
11/26/2024335.21 undefined
11/25/2024337.82 undefined
11/22/2024337.75 undefined
11/21/2024341.82 undefined
11/20/2024326.09 undefined
11/19/2024314.96 undefined
11/18/2024308.93 undefined

Medpace Holdings Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Medpace Holdings, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Medpace Holdings from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Medpace Holdings’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Medpace Holdings. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Medpace Holdings’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Medpace Holdings’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Medpace Holdings’s growth potential.

Medpace Holdings Revenue, EBIT and net profit per share

DateMedpace Holdings RevenueMedpace Holdings EBITMedpace Holdings Net Income
2029e3.6 B undefined788.55 M undefined656.86 M undefined
2028e3.27 B undefined708.56 M undefined581.72 M undefined
2027e2.88 B undefined592.73 M undefined518.48 M undefined
2026e2.55 B undefined521.31 M undefined450.76 M undefined
2025e2.28 B undefined456.75 M undefined395.98 M undefined
2024e2.15 B undefined439.28 M undefined377.84 M undefined
20231.89 B undefined336.83 M undefined282.62 M undefined
20221.46 B undefined278.7 M undefined245.2 M undefined
20211.14 B undefined198.6 M undefined181.4 M undefined
2020925.9 M undefined167 M undefined144.9 M undefined
2019861 M undefined127.3 M undefined100.2 M undefined
2018704.6 M undefined101 M undefined72.9 M undefined
2017436.2 M undefined64.9 M undefined39 M undefined
2016421.6 M undefined52.5 M undefined13.4 M undefined
2015359.1 M undefined29.9 M undefined-8.7 M undefined
2014326.4 M undefined26 M undefined-15.6 M undefined
2013272.9 M undefined58.9 M undefined24.8 M undefined

Medpace Holdings Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
0.270.330.360.420.440.70.860.931.141.461.892.152.282.552.883.273.6
-19.8510.1217.273.5661.4722.307.4323.4627.8529.1114.065.8612.0812.7413.8010.08
45.5940.8043.4540.8639.9130.5428.4630.0528.7229.5927.8024.3723.0220.5418.2216.0114.54
124133156172174215245278328432524000000
24-15-8133972100144181245282377395450518581656
--162.50-46.67-262.50200.0084.6238.8944.0025.6935.3615.1033.694.7713.9215.1112.1612.91
39.639.639.636.339.836.937.637.737.733.731.84000000
-----------------
Details

Keystats

ⓘ

Revenue and Growth

The Medpace Holdings Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Medpace Holdings is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (k)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
2014201520162017201820192020202120222023
                   
54.314.937.126.523.3131.9277.8461.328.3245.45
65.265.179.883.1133.4155.7161186.4253.4298.4
0000000000
0000000000
13.814.816.420.421.429.434.943.252.349.98
133.394.8133.3130178.1317473.7690.9334593.83
38.137.543.848.752.399.4198.8222.7248.9265.39
0000000000
0000000000
249.9186.7136.198.769.254.446.541.43835.81
670.3661661661661662.4662.4662.4662.4662.4
5.34.1512.37.49.99.342.669.299.41
0.960.890.850.820.790.830.920.971.021.06
1.10.980.980.950.971.141.391.661.351.66
                   
300300400400400400400400300308
417.6438.7623.6630.3639.4666.6695.9727.9770.8802.68
-14.3-23-9.6-120.4-41.568.1115.2235-359.8-221.65
-1.6-2.6-3.7-0.7-2.5-2.7-0.1-4.8-12.4-10.07
0000000000
402413.4610.7509.6595.8732.4811.4958.5398.9571.27
6.38.710.916.716.722.426.625.733.131.87
20.320.124.423.787.5120.2150.3175.6229.4315.33
107.1105.2120.9135.9152.8200.4263.3356491577.94
00000000500
0012.416.5000000
133.7134168.6192.8257343440.2557.3803.5925.13
523.4408.2179.8231.7104.200000
33.821.112124.212.813.61.11.12.4
4.27.3810.712.860.9131.2148.7161.6170.34
561.4436.6199.8254.4121.273.7144.8149.8162.7172.75
0.70.570.370.450.380.420.590.710.971.1
1.10.980.980.960.971.151.41.671.371.67
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Medpace Holdings provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Medpace Holdings's financial health and stability.

Assets

Medpace Holdings's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Medpace Holdings must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Medpace Holdings after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Medpace Holdings's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
20132014201520162017201820192020202120222023
24-15-8133973100145181245282
3068695846382319212226
6-9-12-933100-37-23-25
2817371239356666106106
10145431075340455863
000166710023
0001717231323565076
9875849197156201258263388433
-4-5-6-13-12-16-17-31-28-36-36
-4-908-6-13-12-17-19-31-31-38-34
0-9030000-10-3-12
00000000000
-96477-117-22755-144-800050-50
14140174-15326-82-44-825-132
-95882-116-58-97-141-73-82-44-775-182
-1.00-9.00--4.00-------
00000000000
-248-3919-10-3108145183-433217
93.57077.678.285.1140.6184227.4235351.2396.73
00000000000

Medpace Holdings stock margins

The Medpace Holdings margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Medpace Holdings. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Medpace Holdings.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Medpace Holdings's sales revenue. A higher gross margin percentage indicates that the Medpace Holdings retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Medpace Holdings's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Medpace Holdings's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Medpace Holdings's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Medpace Holdings. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Medpace Holdings's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Medpace Holdings Margin History

Medpace Holdings Gross marginMedpace Holdings Profit marginMedpace Holdings EBIT marginMedpace Holdings Profit margin
2029e27.81 %21.89 %18.23 %
2028e27.81 %21.64 %17.77 %
2027e27.81 %20.61 %18.03 %
2026e27.81 %20.44 %17.67 %
2025e27.81 %20.07 %17.4 %
2024e27.81 %20.43 %17.57 %
202327.81 %17.86 %14.99 %
202229.62 %19.09 %16.79 %
202128.73 %17.38 %15.88 %
202030.1 %18.04 %15.65 %
201928.54 %14.79 %11.64 %
201830.58 %14.33 %10.35 %
201740.05 %14.88 %8.94 %
201640.82 %12.45 %3.18 %
201543.55 %8.33 %-2.42 %
201440.96 %7.97 %-4.78 %
201345.62 %21.58 %9.09 %

Medpace Holdings Stock Sales Revenue, EBIT, Earnings per Share

The Medpace Holdings earnings per share therefore indicates how much revenue Medpace Holdings has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Medpace Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Medpace Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Medpace Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Medpace Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Medpace Holdings Revenue, EBIT and net profit per share

DateMedpace Holdings Sales per ShareMedpace Holdings EBIT per shareMedpace Holdings Earnings per Share
2029e115.93 undefined0 undefined21.13 undefined
2028e105.34 undefined0 undefined18.72 undefined
2027e92.54 undefined0 undefined16.68 undefined
2026e82.08 undefined0 undefined14.5 undefined
2025e73.23 undefined0 undefined12.74 undefined
2024e69.18 undefined0 undefined12.16 undefined
202359.23 undefined10.58 undefined8.88 undefined
202243.32 undefined8.27 undefined7.28 undefined
202130.3 undefined5.27 undefined4.81 undefined
202024.56 undefined4.43 undefined3.84 undefined
201922.9 undefined3.39 undefined2.66 undefined
201819.09 undefined2.74 undefined1.98 undefined
201710.96 undefined1.63 undefined0.98 undefined
201611.61 undefined1.45 undefined0.37 undefined
20159.07 undefined0.76 undefined-0.22 undefined
20148.24 undefined0.66 undefined-0.39 undefined
20136.89 undefined1.49 undefined0.63 undefined

Medpace Holdings business model

The company Medpace Holdings Inc is a global company specializing in conducting clinical trials and providing R&D services in the pharmaceutical and biotech industry. Medpace was founded in 1992 by Dr. August Troendle and is headquartered in Cincinnati, Ohio. Medpace's business model is based on offering a variety of services to pharmaceutical and biotech companies as a contract research organization (CRO), ranging from planning and conducting clinical trials to their evaluation. This includes regulatory consulting services, project management and data management, as well as monitoring and quality assurance. Medpace specializes in conducting complex studies for testing and approval of new drugs or medical technology products. However, the company also has experience in conducting post-marketing studies and supporting products that are already established in the global markets. Medpace's various divisions cover a wide range of therapy areas, from oncology and cardiovascular diseases to rare diseases and infectious diseases. The company has worked in over 60 countries and has 35 offices worldwide, including in Europe, Asia, and South America. Medpace has earned a reputation as a trusted partner in the planning, conducting, and evaluation of clinical trials and works closely with clients to understand their needs and requirements. The company has extensive experience working with regulatory authorities around the world and supports its clients in compliance with applicable regulations and requirements. Medpace's product portfolio includes a wide range of services tailored to the individual needs of its clients. These include: - Clinical trial management: Medpace supports clients in all aspects of planning, conducting, and monitoring clinical trials, including budget, personnel, and resource management. - Data management: Medpace offers comprehensive data management solutions, including data capture, validation, and storage, as well as a web-based platform for real-time data retrieval. - Regulatory consulting: Medpace provides support in all aspects of regulatory requirements, from preparation and submission of regulatory applications to monitoring and maintaining approvals. - Medical monitoring: Medpace provides experienced medical personnel to monitor the safety of study participants and assist in the monitoring of adverse events and interpretation of medical data. - Quality management: Medpace has a comprehensive quality management system that ensures all clinical trials are conducted according to the highest quality standards. Over the years, Medpace has received numerous awards and recognitions and is valued by its clients for its high quality, flexibility, and innovation. The company is constantly striving to improve its services and processes to meet the changing needs of the industry. Medpace Holdings is one of the most popular companies on Eulerpool.com.

Medpace Holdings SWOT Analysis

Strengths

Medpace Holdings Inc has several strengths that contribute to its success in the market. Firstly, the company has a strong reputation and expertise in the clinical research and development industry. This positions Medpace as a trusted partner for pharmaceutical and biotechnology companies, leading to a solid customer base and long-term collaborations.

Additionally, Medpace possesses a highly skilled and dedicated workforce. The company's employees are experienced professionals who provide outstanding support and guidance throughout the clinical trial process. This expertise allows Medpace to deliver high-quality services, ensuring accurate and reliable results for clients.

Weaknesses

Despite its strengths, Medpace Holdings Inc faces certain weaknesses that could pose challenges. One notable weakness is the company's geographic concentration. Medpace primarily operates in North America and Europe, which limits its market reach compared to competitors with a more global presence. This makes it vulnerable to regional economic fluctuations and regulatory changes.

Another weakness is that Medpace relies heavily on a few key clients for a significant portion of its revenue. This client concentration exposes the company to the risk of losing a major customer, potentially leading to a decline in revenue and profitability.

Opportunities

There are several opportunities available to Medpace Holdings Inc that can enable further growth and expansion. Firstly, the increasing demand for clinical research and development presents a significant opportunity for Medpace to capitalize on. As the pharmaceutical and biotechnology industries continue to evolve, there is a growing need for reliable clinical trial services, which Medpace is well-positioned to provide.

Additionally, Medpace can explore opportunities to expand into emerging markets. By establishing a presence in regions like Asia and Latin America, the company can tap into new customer segments and diversify its revenue streams. This would reduce its reliance on specific geographic markets and open up potential growth avenues.

Threats

Medpace Holdings Inc is not immune to threats that could impact its performance and market position. External competition is a key threat, as the clinical research and development industry is highly competitive. Medpace must continuously innovate and differentiate itself to stay ahead of competitors and maintain its market share.

Moreover, regulatory and legal uncertainties pose a threat to Medpace's operations. Changes in regulations pertaining to clinical trials or data privacy can significantly impact the company's ability to conduct its business smoothly. Medpace must closely monitor and adapt to changes in the regulatory landscape to mitigate this threat effectively.

Medpace Holdings Revenue by Segment

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Medpace Holdings Revenue by Segment

Segmente202320222021202020192018
Revenue net1.89 B USD1.46 B USD----
Oncology587.1 M USD467.8 M USD----
Other404.84 M USD296.91 M USD----
Metabolic376.84 M USD244.68 M USD----
Cardiology193.69 M USD174.63 M USD----
Central Nervous System160.06 M USD157.94 M USD----
AVAI163.31 M USD118.03 M USD----

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Medpace Holdings Revenue by Segment

Segmente202320222021202020192018
Total Revenue--1.14 B USD---
Revenue, net---925.93 M USD--
Oncology----256.77 M USD189.03 M USD
Other----222.51 M USD161.19 M USD
Metabolic----138.65 M USD94.13 M USD
Cardiology----91.26 M USD91.82 M USD
Antiviral and anti-infective----86.39 M USD76.74 M USD
Central nervous system----65.39 M USD53.9 M USD
Endocrine-----26 M USD
Medical devices-----11.77 M USD

  • 3 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Medpace Holdings Revenue by Segment

Segmente202320222021202020192018
Oncology--362.85 M USD297.68 M USD--
Other--267.42 M USD215.37 M USD--
Metabolic--159.9 M USD126.08 M USD--
Cardiology--119.69 M USD95.15 M USD--
Central Nervous System--121.55 M USD---
AVAI--110.98 M USD---
Antiviral and anti-infective---103.26 M USD--
Central nervous system---88.39 M USD--

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Medpace Holdings Revenue by Segment

Segmente202320222021202020192018
Revenue, net----860.97 M USD704.59 M USD
Direct revenue-----478.06 M USD
Reimbursed out of pocket revenue-----71.31 M USD
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Medpace Holdings Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Medpace Holdings historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Medpace Holdings shares outstanding

The number of shares was Medpace Holdings in 2023 — This indicates how many shares 31.841 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Medpace Holdings earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Medpace Holdings's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Medpace Holdings’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Medpace Holdings's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Medpace Holdings.

Medpace Holdings latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/20242.83 3.01  (6.19 %)2024 Q3
6/30/20242.59 2.75  (6.28 %)2024 Q2
3/31/20242.51 3.2  (27.27 %)2024 Q1
12/31/20232.27 2.46  (8.54 %)2023 Q4
9/30/20232.09 2.22  (6.38 %)2023 Q3
6/30/20231.95 1.93  (-1.18 %)2023 Q2
3/31/20231.84 2.27  (23.57 %)2023 Q1
12/31/20221.82 2.12  (16.37 %)2022 Q4
9/30/20221.5 2.05  (36.37 %)2022 Q3
6/30/20221.34 1.46  (9.1 %)2022 Q2
1
2
3
4

Eulerpool ESG Scorecard© for the Medpace Holdings stock

Eulerpool World ESG Rating (EESG©)

67/ 100

🌱 Environment

55

👫 Social

99

🏛️ Governance

48

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees67
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Medpace Holdings shareholders

%
Name
Stocks
Change
Date
15.22850 % Medpace Investors, L.L.C.4,733,019-380,0003/21/2024
8.11486 % The Vanguard Group, Inc.2,522,09722,9076/30/2024
7.43782 % BlackRock Institutional Trust Company, N.A.2,311,676116,0676/30/2024
3.11224 % Wasatch Global Investors Inc967,283-7,1326/30/2024
2.26076 % State Street Global Advisors (US)702,6455,6866/30/2024
2.10636 % Troendle (August J)654,656-135,0575/28/2024
1.87800 % Geode Capital Management, L.L.C.583,68350,9346/30/2024
1.82280 % Goldman Sachs Asset Management, L.P.566,525100,7796/30/2024
1.77492 % Riverbridge Partners, LLC551,64415,6489/30/2024
1.64501 % TD Asset Management Inc.511,268-62,8816/30/2024
1
2
3
4
5
...
10

Medpace Holdings Executives and Management Board

Dr. August Troendle

(66)
Medpace Holdings Chairman of the Board, Chief Executive Officer (since 1992)
Compensation 1.89 M

Ms. Susan Burwig

(60)
Medpace Holdings Executive Vice President - Operations
Compensation 1.21 M

Mr. Jesse Geiger

(48)
Medpace Holdings President
Compensation 1.08 M

Mr. Stephen Ewald

(53)
Medpace Holdings General Counsel, Corporate Secretary
Compensation 1.03 M

Mr. Kevin Brady

(48)
Medpace Holdings Chief Financial Officer, Treasurer
Compensation 843,043
1
2
3

Most common questions regarding Medpace Holdings

What values and corporate philosophy does Medpace Holdings represent?

Medpace Holdings Inc represents a strong commitment to quality, integrity, and innovation in the clinical research industry. As a leading global contract research organization (CRO), Medpace is dedicated to providing high-quality, comprehensive services to pharmaceutical and biotechnology companies. The company follows a customer-centric approach and strives to exceed expectations by delivering customized solutions tailored to each client's needs. Medpace emphasizes collaboration, transparency, and scientific excellence in its operations, fostering partnerships with clients and prioritizing the advancement of medical breakthroughs. With its robust corporate philosophy, Medpace continues to drive advancements in drug development and shape the future of clinical research.

In which countries and regions is Medpace Holdings primarily present?

Medpace Holdings Inc is primarily present in various countries and regions worldwide. With a global presence, Medpace operates in North America, Europe, Asia-Pacific, and other emerging markets. The company has established offices and clinical research sites in numerous countries, including the United States, Canada, France, Germany, Belgium, the Netherlands, India, China, Japan, Singapore, and Australia. Being a leading clinical contract research organization, Medpace collaborates with pharmaceutical, biotechnology, and medical device companies across these regions to provide high-quality clinical research services.

What significant milestones has the company Medpace Holdings achieved?

Medpace Holdings Inc, a leading clinical research organization, has achieved notable milestones. The company successfully completed its initial public offering (IPO) in August 2016, marking a significant milestone in its growth trajectory. Medpace has consistently demonstrated its commitment to quality and innovation, which led to its inclusion in the S&P SmallCap 600 Index in 2018. Furthermore, the company expanded its global footprint by establishing offices in Australia, Singapore, and South Korea. Medpace's dedication to advancing medical research and providing exceptional services has earned it recognition as a top CRO (Contract Research Organization) by industry publications.

What is the history and background of the company Medpace Holdings?

Medpace Holdings Inc. is a pharmaceutical contract research organization that provides comprehensive clinical research services to the biotechnology, pharmaceutical, and medical device industries. Founded in 1992 by Dr. August Troendle, Medpace has since grown to become a leading global player in the clinical research industry. With a focus on developing innovative and efficient drug development strategies, Medpace offers services ranging from site feasibility assessments to full-service clinical trial management. The company's team of experienced industry professionals and its commitment to quality and timeliness have propelled Medpace to great success in its mission to accelerate the development of safe and effective medical therapies.

Who are the main competitors of Medpace Holdings in the market?

The main competitors of Medpace Holdings Inc in the market include PRA Health Sciences, ICON plc, and Syneos Health.

In which industries is Medpace Holdings primarily active?

Medpace Holdings Inc is primarily active in the contract research organization (CRO) industry. As a leading global CRO, Medpace provides various services to support the development of pharmaceutical, biotechnology, and medical device products. With its expertise in clinical research, regulatory affairs, and medical writing, Medpace assists companies in navigating the complex process of bringing new therapies to market. Additionally, Medpace works across a range of therapeutic areas, including cardiovascular, oncology, neurology, and infectious diseases. Through its comprehensive services and industry experience, Medpace contributes to advancements in healthcare by facilitating the efficient and innovative development of new medical treatments and therapies.

What is the business model of Medpace Holdings?

Medpace Holdings Inc is a clinical contract research organization (CRO) that provides services to pharmaceutical, biotechnology, and medical device companies. The company's business model revolves around offering comprehensive clinical trial management services, including protocol and study design, site selection and management, data management, and regulatory consulting. Medpace's CRO expertise enables efficient and successful execution of clinical trials in various therapeutic areas. With a focus on quality, accuracy, and compliance, Medpace is committed to facilitating the development of innovative pharmaceutical products to improve patient care.

What is the P/E ratio of Medpace Holdings 2024?

The Medpace Holdings P/E ratio is 30.36.

What is the P/S ratio of Medpace Holdings 2024?

The Medpace Holdings P/S ratio is 5.34.

What is the Quality Investing of Medpace Holdings?

The Quality Investing for Medpace Holdings is 8/10.

What is the revenue of Medpace Holdings 2024?

The expected Medpace Holdings revenue is 2.15 B USD.

How high is the profit of Medpace Holdings 2024?

The expected Medpace Holdings profit is 377.84 M USD.

What is the business model of Medpace Holdings

Medpace Holdings Inc. is a leading company in the clinical research industry. The company offers a wide range of clinical study services to its customers in the pharmaceutical, biotechnology, and medical device industries. The company is headquartered in Cincinnati, Ohio, USA and has more than 4,500 employees in 47 countries worldwide. Medpace operates its business through three segments: 1. Medpace Clinical Pharmacology Services (MCPS) 2. Medpace Research Operations (MRO) 3. Medpace Medical Device Division (MDD) Medpace Clinical Pharmacology Services (MCPS) is responsible for conducting phase I studies, which aim to test the safety and tolerability of new drugs, vaccines, or other therapies. Small groups of healthy volunteers are studied in a clinical setting to collect data that can later be used in advanced studies to evaluate the effectiveness of a product. Medpace Research Operations (MRO) covers a broader range of clinical studies, such as phase II, phase III, and post-marketing studies. The focus here is to assess the effectiveness and safety of drugs or medical devices in a larger number of patients. Medpace Medical Device Division (MDD) offers a wide range of services for evaluating the safety and effectiveness of medical devices and implants. The company employs a group of experienced experts who help in the development and conduct of clinical studies involving medical devices and implants. Medpace also offers its customers a variety of supportive services, such as data management, biostatistics, and medical monitoring. The company has also developed its own electronic data management platform, which provides a high level of efficiency and accuracy in conducting clinical studies. It is worth mentioning that Medpace does not offer products in the traditional sense. Instead, the services offered are supportive services for conducting clinical studies. However, Medpace is an important partner for leading pharmaceutical and medical companies worldwide, benefiting from Medpace's professional and excellent planning and execution of clinical studies. Medpace's business model is based on providing high-quality clinical study services that help its customers bring innovative therapies and medications to the market. Medpace is in a key position in the global clinical research industry and can rely on a strong market position and experienced team of experts.

What is the Medpace Holdings dividend?

Medpace Holdings pays a dividend of 0 USD distributed over payouts per year.

How often does Medpace Holdings pay dividends?

The dividend cannot currently be calculated for Medpace Holdings or the company does not pay out a dividend.

What is the Medpace Holdings ISIN?

The ISIN of Medpace Holdings is US58506Q1094.

What is the Medpace Holdings WKN?

The WKN of Medpace Holdings is A2APTV.

What is the Medpace Holdings ticker?

The ticker of Medpace Holdings is MEDP.

How much dividend does Medpace Holdings pay?

Over the past 12 months, Medpace Holdings paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Medpace Holdings is expected to pay a dividend of 0 USD.

What is the dividend yield of Medpace Holdings?

The current dividend yield of Medpace Holdings is .

When does Medpace Holdings pay dividends?

Medpace Holdings pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Medpace Holdings?

Medpace Holdings paid dividends every year for the past 0 years.

What is the dividend of Medpace Holdings?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Medpace Holdings located?

Medpace Holdings is assigned to the 'Health' sector.

Wann musste ich die Aktien von Medpace Holdings kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Medpace Holdings from 12/17/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/17/2024.

When did Medpace Holdings pay the last dividend?

The last dividend was paid out on 12/17/2024.

What was the dividend of Medpace Holdings in the year 2023?

In the year 2023, Medpace Holdings distributed 0 USD as dividends.

In which currency does Medpace Holdings pay out the dividend?

The dividends of Medpace Holdings are distributed in USD.

All fundamentals about Medpace Holdings

Our stock analysis for Medpace Holdings Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Medpace Holdings Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.